guadecitabine (SGI-110) / Otsuka  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
guadecitabine (SGI-110) / Otsuka
NCT02901899: Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed
2
45
US
Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Northwestern University, Merck Sharp & Dohme LLC, Astex Pharmaceuticals, Inc., National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
04/20
03/23
2019-002986-36: A randomized, run-in, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1 Studio di fase II randomizzato con la combinazione nivolumab, ipilimumab e guadecitabina o la combinazione nivolumab e ipilimumab in pazienti affetti da melanoma e carcinoma polmonare non a piccole cellule metastatico resistente ad anti-PD-1/PD-L1

Ongoing
2
184
Europe
YERVOY, Guadecitabine, OPDIVO, [NA], [SGI-110], [na], Concentrate for solution for infusion, Lyophilisate for solution for injection, Solution for infusion
FONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI, Bristol-Myers Squibb S.r.l, Astex Pharmaceutical, Inc
MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy pazienti con melanoma metastatico (MM) e tumore del polmone non a piccole cellule (NSCLC) in stadio IV, che hanno ricevuto e sono progrediti a precedenti trattamenti con farmaci immunoterapici anti-PD-1/(-PD-L1), MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy pazienti con melanoma metastatico (MM) e tumore del polmone non a piccole cellule (NSCLC) in stadio IV, che hanno ricevuto e sono progrediti a precedenti trattamenti immunoterapici anti-PD-1/(-PD-L1), Diseases [C] - Cancer [C04]
 
 
NCT03913455: Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Completed
2
24
US
Guadecitabine, SGI-110, Carboplatin, Platinol
Shadia Jalal, MD, Astex Pharmaceuticals, Inc., Indiana University School of Medicine
Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
04/21
02/22
NIBIT-ML1, NCT04250246: A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1

Not yet recruiting
2
184
Europe
Ipilimumab plus nivolumab plus guadecitabine, ipilimumab (Yervoy), nivolumab (Opdivo), guadecitabine (SGI-110), Ipilimumab plus nivolumab
Italian Network for Tumor Biotherapy Foundation, Astex Pharmaceuticals, Inc., Bristol-Myers Squibb
Melanoma, Non Small Cell Lung Cancer
03/23
03/25
2015-004062-29: SPIRE - A phase Ib/randomised IIa open label clinical trial combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer

Ongoing
1/2
56
Europe
Guadecitabine (SGI-110), Cisplatin, Gemcitabine, SGI-110, Powder for injection, Concentrate for solution for injection/infusion, Powder for infusion
University Hospital Southampton NHS Trust, Cancer Research UK, Astex Pharmaceuticals
Solid Malignancies including Bladder Cancer, Bladder Cancer, Diseases [C] - Cancer [C04]
 
 
BTCRC GU16-043, NCT03308396: Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Active, not recruiting
1/2
57
US
Guadecitabine, SGI-110, Durvalumab, MEDI4736
Ajjai Alva, MD, AstraZeneca, Big Ten Cancer Research Consortium
Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma
12/22
12/23

Download Options